Edwards Lifesciences logo

EW - Edwards Lifesciences Share Price

$95.24 5.6  6.3%

Last Trade - 21/04/21

Large Cap
Market Cap ÂŁ42.70bn
Enterprise Value ÂŁ42.17bn
Revenue ÂŁ3.21bn
Position in Universe 209th / 6852
Unlock EW Revenue
Relative Strength (%)
1m +13.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -0.75%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2,494 2,964 3,435 3,723 4,348 4,386 5,132 5,708 +12.0%
+48.0 +25.4 +40.7 +22.6 +9.1 +5.0 +15.8 +15.0
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, EdwardsLifesciences Corp revenues increased 8% to $1.22B. Netincome increased 9% to $338.2M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net income benefitedfrom Intellectual property litigation expense decrease of49% to $6.4M (expense), Change in fair value of contingentconsi increase from $2.2M to $4.5M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for EW
Graphical History


EW Revenue Unlock EW Revenue

Net Income

EW Net Income Unlock EW Revenue

Normalised EPS

EW Normalised EPS Unlock EW Revenue

PE Ratio Range

EW PE Ratio Range Unlock EW Revenue

Dividend Yield Range

EW Dividend Yield Range Unlock EW Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
EW EPS Forecasts Unlock EW Revenue
Profile Summary

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated September 10, 1999
Public Since March 27, 2000
No. of Shareholders: 8,876
No. of Employees: 14,900
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange New York Stock Exchange
Shares in Issue 624,518,873
Free Float (0.0%)
Eligible for
EW Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for EW
Upcoming Events for EW
Tuesday 4th May, 2021
Edwards Lifesciences Corp Annual Shareholders Meeting
Friday 7th May, 2021 Estimate
Edwards Lifesciences Corp Annual Shareholders Meeting
Wednesday 21st July, 2021 Estimate
Q2 2021 Edwards Lifesciences Corp Earnings Release
Tuesday 19th October, 2021 Estimate
Q3 2021 Edwards Lifesciences Corp Earnings Release
Frequently Asked Questions for Edwards Lifesciences
What is the Edwards Lifesciences share price?

As of 21/04/21, shares in Edwards Lifesciences are trading at $95.24, giving the company a market capitalisation of ÂŁ42.70bn. This share price information is delayed by 15 minutes.

How has the Edwards Lifesciences share price performed this year?

Shares in Edwards Lifesciences are currently trading at $95.24 and the price has moved by 32.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Edwards Lifesciences price has moved by -10.46% over the past year.

What are the analyst and broker recommendations for Edwards Lifesciences?

Of the analysts with advisory recommendations for Edwards Lifesciences, there are there are currently 7 "buy" , 10 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Edwards Lifesciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Edwards Lifesciences next release its financial results?

Edwards Lifesciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Edwards Lifesciences dividend yield?

Edwards Lifesciences does not currently pay a dividend.

Does Edwards Lifesciences pay a dividend?

Edwards Lifesciences does not currently pay a dividend.

When does Edwards Lifesciences next pay dividends?

Edwards Lifesciences does not currently pay a dividend.

How do I buy Edwards Lifesciences shares?

To buy shares in Edwards Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Edwards Lifesciences?

Shares in Edwards Lifesciences are currently trading at $95.24, giving the company a market capitalisation of ÂŁ42.70bn.

Where are Edwards Lifesciences shares listed? Where are Edwards Lifesciences shares listed?

Here are the trading details for Edwards Lifesciences:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: EW
What kind of share is Edwards Lifesciences?

Based on an overall assessment of its quality, value and momentum, Edwards Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Edwards Lifesciences share price forecast 2021?

Shares in Edwards Lifesciences are currently priced at $95.24. At that level they are trading at 2.79% discount to the analyst consensus target price of 0.00.

Analysts covering Edwards Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of 2.177 for the next financial year.

How can I tell whether the Edwards Lifesciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Edwards Lifesciences. Over the past six months, the relative strength of its shares against the market has been -2.58%. At the current price of $95.24, shares in Edwards Lifesciences are trading at 15.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Edwards Lifesciences PE Ratio?

The Edwards Lifesciences PE ratio based on its reported earnings over the past 12 months is 54.04. The shares are currently trading at $95.24.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Edwards Lifesciences?

Edwards Lifesciences's management team is headed by:

Michael Mussallem - CHM
Huimin Wang - VPR
Larry Wood - VPR
Donald Bobo - VPR
William Link - IND
Scott Ullem - CFO
Kieran Gallahue - IND
Catherine Szyman - VPR
Martha Marsh - LED
Leslie Heisz - IND
Jean-Luc Lemercier - CEX
Daveen Chopra - VPR
Paul LaViolette - IND
Who are the major shareholders of Edwards Lifesciences?

Here are the top five shareholders of Edwards Lifesciences based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.74% (48.3m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.34% (33.3m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.14% (25.9m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 2.93% (18.3m shares)
Capital International Investors Investment Advisor
Percentage owned: 2.86% (17.8m shares)
Similar to EW
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.